Radiotherapy and chemotherapy
Screening and early diagnosis
This will be the second international event on pancreatic cancer in Marseille. Pancreatic cancer is the 12th most commonly occurring cancer in men and the 11th most commonly occurring cancer in women. Pancreatic cancer has the lowest survival of all cancers in Europe. Responsible for over 95,000 EU deaths every year, the median survival time at the point of diagnosis is just 4.6 months, with patients losing 98% of their healthy life expectancy. Often referred to as ‘the silent killer’, symptoms can be hard to identify, thus making it difficult to diagnose the disease early which is essential for life-saving surgery. There were 460,000 new cases in 2018.
We have selected topics that translational and clinical pancreatic cancer research and therapy, including sessions on diagnostics, screening and therapy that have the potential to directly impact survival rates. Other topics that will be presented include genetic testing, immunology and immunotherapy, management of local disease, metabolism and metabolomics, precision medicine, signaling and oncogenes, and the tumor microenvironment. This meeting should be interactive with the participants, sessions as “meet the experts” and poster presentations are scheduled.
Save the date and join us the 16 and 17 January 2020 at the Palais du Pharo, one the nicest place of Marseille.
The Organisation Committee
Partners and sponsors
PCHM is the place to be to meet cancer specialists, surgeons, endocrinologists, radiotherapists, oncologists, radiologists and pathologists.
580 sqm of exhibition are available to manufacturers, distributors, laboratories and service providers who wish to present their products.
To get more information about partnership, contact us
We are pleased to announce that PCHM will organise a call for submissions for poster exhibition. The goal of the poster exhibition is to present clinical studies, achievements, tools and projects related to pancreatic cancer.
More information about requested topics and guidelines here.